Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8100140rdf:typepubmed:Citationlld:pubmed
pubmed-article:8100140lifeskim:mentionsumls-concept:C0026986lld:lifeskim
pubmed-article:8100140lifeskim:mentionsumls-concept:C1704387lld:lifeskim
pubmed-article:8100140lifeskim:mentionsumls-concept:C0872076lld:lifeskim
pubmed-article:8100140lifeskim:mentionsumls-concept:C0241764lld:lifeskim
pubmed-article:8100140lifeskim:mentionsumls-concept:C0035268lld:lifeskim
pubmed-article:8100140lifeskim:mentionsumls-concept:C0439659lld:lifeskim
pubmed-article:8100140pubmed:issue4lld:pubmed
pubmed-article:8100140pubmed:dateCreated1993-7-26lld:pubmed
pubmed-article:8100140pubmed:abstractTextRestriction fragment length polymorphisms (RFLP) of the X-chromosome genes phosphoglycerate kinase (PGK) and hypoxanthine phorphoribosyltransferase (HPRT) were used to determine the clonal nature of myelodysplastic syndromes (MDS) in 22 patients. These included eight with refractory anaemia (RA), four with RA with ring sideroblasts (RARS), six with RA with an excess of blasts (RAEB), three with RAEB in transformation (RAEB-T), and one with chronic myelomonocytic leukaemia (CMML). Monoclonal X-inactivation patterns were observed in 19/22 patients. The remaining three cases, one each with RA, RARS and RAEB, were of polyclonal composition. Separated T-lymphocyte and granulocyte fraction analyses in six patients of the former cases revealed that T-lymphocyte as well as granulocyte fractions showed a monoclonal pattern of X-inactivation. These results support the view that the majority of MDS arise from a pluripotent stem cell capable of myeloid and lymphoid differentiation.lld:pubmed
pubmed-article:8100140pubmed:languageenglld:pubmed
pubmed-article:8100140pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8100140pubmed:citationSubsetIMlld:pubmed
pubmed-article:8100140pubmed:statusMEDLINElld:pubmed
pubmed-article:8100140pubmed:monthAprlld:pubmed
pubmed-article:8100140pubmed:issn0007-1048lld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:MoritaKKlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:MaeharaTTlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:OkamotoKKlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:NaruseTTlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:OmineMMlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:TsukamotoNNlld:pubmed
pubmed-article:8100140pubmed:authorpubmed-author:KarasawaMMlld:pubmed
pubmed-article:8100140pubmed:issnTypePrintlld:pubmed
pubmed-article:8100140pubmed:volume83lld:pubmed
pubmed-article:8100140pubmed:ownerNLMlld:pubmed
pubmed-article:8100140pubmed:authorsCompleteYlld:pubmed
pubmed-article:8100140pubmed:pagination589-94lld:pubmed
pubmed-article:8100140pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:meshHeadingpubmed-meshheading:8100140-...lld:pubmed
pubmed-article:8100140pubmed:year1993lld:pubmed
pubmed-article:8100140pubmed:articleTitleClonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms.lld:pubmed
pubmed-article:8100140pubmed:affiliationThird Department of Internal Medicine, Gunma University School of Medicine, Japan.lld:pubmed
pubmed-article:8100140pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8100140pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8100140lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8100140lld:pubmed